Table 1 Patients Characteristics
|  | Gra (n = 413) | Palo (n = 414) |
|---|---|---|
Age, ≥60 years | 290 (70.2%) | 291 (70.3%) |
 median (range) | 64 (25–83) | 63 (31–77) |
Gender, male | 309 (74.8%) | 307 (74.2%) |
ECOG Performance Status | ||
 0 | 282 (68.3%) | 276 (66.7%) |
 1 | 126 (30.5%) | 136 (32.9%) |
 2 | 5 (1.2%) | 2 (0.5%) |
Primary tumor site | ||
 Lung | 265 (64.2%) | 245 (59.2%) |
 Esophageal | 58 (14.0%) | 56 (13.5%) |
 Gastric | 51 (12.4%) | 65 (15.7%) |
 Head and neck | 23 (5.6%) | 26 (6.3%) |
 Other | 16 (3.9%) | 22 (5.3%) |
CDDP dose administered (mg/m2) | ||
  < 60 | 67 (16.2%) | 65 (15.7%) |
  ≥ 60, < 70 | 48 (11.6%) | 57 (13.8%) |
  ≥ 70, < 80 | 243 (58.8%) | 227 (54.8%) |
  ≥ 80 | 55 (13.3%) | 65 (15.7%) |
Prior chemotherapy with platinum more than 3 months earlier | 21 (5.1%) | 16 (3.9%) |